Anti-carbamylated Protein Antibodies and Serum Level of 14-3-3 Protein for Early Detection of Rheumatoid Arthritis Patient in Correlation with Rheumatoid Factor, Anti-CCP Antibodies, Disease Activity and Joint Damage using High Frequency Musculoskeletal Ultrasound

Author(s): Sahar A. Ahmed*, Enas M. Darwish, Walaa A. Attya, Mai Samir, Mennatallah Elsayed, Hoda M. Abbas, Marwa D. Hasan

Journal Name: Applied Clinical Research, Clinical Trials and Regulatory Affairs (Discontinued)
Continued as Applied Drug Research, Clinical Trials and Regulatory Affairs)

Volume 7 , Issue 2 , 2020

Graphical Abstract:


Abstract:

Background: Rheumatoid arthritis (RA) is a common progressive chronic inflammatory autoimmune disease which affects mostly small joints, causing pain, swelling, deformity, and disability. Although progress has been made in exploring RA nature, still there is a lot to know about the disease pathogenesis, diagnosis, and treatment.

Aim of the Work: To investigate the role of serum anti-carbamylated protein antibodies and 14-3-3η in the diagnosis of RA compared to rheumatoid factor (RF), anti-CCP antibodies, and highfrequency musculoskeletal ultrasound used to assess the disease activity and joint damage.

Methods: Serum anti-carbamylated protein antibodies and 14-3-3η were measured using ELISA in 61 RA patients and 26 normal controls. RA Disease Activity Score (DAS 28), X-ray and musculoskeletal ultrasound (hands and feet), carotid ultrasound (Intima-Media Thickness {IMT}) were used in assessing the RA disease.

Results: Anti-carbamylated protein antibodies were significantly elevated in RA patients 4.5 (4.1- 8.9 U⁄ml) compared to the control 3.2(1.9- 4.3 U⁄ml) (p< 0.001) but 14-3-3η showed no significant difference. There was a significant positive correlation between anti-carbamylated protein antibodies, 14-3-3η levels and disease activity score assessed by DAS 28, increased IMT measured by carotid duplex, total synovitis and total erosion score were assessed by musculoskeletal ultrasound. There was no correlation between RF and anti-CCP antibodies. Anti-carbamylated protein antibodies were found to have 66.7% sensitivity and 85.2% specificity in RA diagnosis, while 14-3-3η had 51.9% sensitivity and 72.1% specificity.

Conclusion: Anti-carbamylated protein antibodies and 14-3-3η have a high sensitivity and specificity in RA diagnosis and had a correlation with the disease activity and joint damage.

Keywords: Rheumatoid arthritis, anti-carbamylated antibodies, 14-3-3η, musculoskeletal ultrasound, polyarthritis, diagnosis.

[1]
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376(9746): 1094-108.
[http://dx.doi.org/10.1016/S0140-6736(10)60826-4] [PMID: 20870100]
[2]
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016; 388: 2023-38.
[3]
Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48(1): 54-8.
[http://dx.doi.org/10.1002/art.10705] [PMID: 12528103]
[4]
Verheul MK, Fearon U, Trouw LA, Veale DJ. Biomarkers for rheumatoid and psoriatic arthritis. Clin Immunol 2015; 161(1): 2-10.
[http://dx.doi.org/10.1016/j.clim.2015.04.005] [PMID: 25934385]
[5]
Mäkinen H, Kaarela K, Huhtala H, Hannonen PJ, Korpela M, Sokka T. Do the 2010 ACR/EULAR or ACR 1987 classification criteria predict erosive disease in early arthritis? Ann Rheum Dis 2012; 72-5.
[6]
Value of measuring anti-carbamylated protein antibodiesforclassification on early arthritis patients. Scientific reports 2017; 7: 12023.
[http://dx.doi.org/10.1038/s41598-017-09657-5]
[7]
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
[http://dx.doi.org/10.1056/NEJMra1004965] [PMID: 22150039]
[8]
Vidal-Bralo L, Perez-Pampin E, Regueiro C, et al. Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients. PLoS One 2017; 12(7),e0180144.
[http://dx.doi.org/10.1371/journal.pone.0180144] [PMID: 28672020]
[9]
Jaisson S, Pietrement C, Gillery P. Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem 2011; 57(11): 1499-505.
[http://dx.doi.org/10.1373/clinchem.2011.163188] [PMID: 21768218]
[10]
Verheul MK, Vierboom MPM, Hart BA, Toes REM, Trouw LA. Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis. Arthritis Res Ther 2017; 19(1): 246.
[http://dx.doi.org/10.1186/s13075-017-1455-1] [PMID: 29096669]
[11]
Willemze A, Toes REM, Huizinga TWJ, Trouw LA. Trouw: new biomarkers in rheumatoid arthritis Netherlands J of Med 2012; 7: 9
[12]
Wynckel A, Randoux C, Millart H, et al. Kinetics of carbamylated hemoglobin in acute renal failure. Nephrol Dial Transplant 2000; 15(8): 1183-8.
[http://dx.doi.org/10.1093/ndt/15.8.1183] [PMID: 10910442]
[13]
Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007; 13(10): 1176-84.
[http://dx.doi.org/10.1038/nm1637] [PMID: 17828273]
[14]
Ibrahim SE, Morshedy NA, Farouk N, Louka AL. Anti-carbamylated protein antibodies in psoriatic arthritis patients: relation to disease activity, severity and ultrasonographic scores. Egypt Rheumatol 2018; 40: 17-21.
[http://dx.doi.org/10.1016/j.ejr.2017.08.002]
[15]
Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011; 108(42): 17372-7.
[http://dx.doi.org/10.1073/pnas.1114465108] [PMID: 21987802]
[16]
Ajeganova S, Humphreys JH, Verheul MK, et al. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Ann Rheum Dis 2016; 75(11): 1924-32.
[http://dx.doi.org/10.1136/annrheumdis-2015-208579] [PMID: 26757747]
[17]
Maksymowych WP, Marotta A. 14-3-3η: a novel biomarker platform for rheumatoid arthritis. Clin Exp Rheumatol 2014; 32(5)(Suppl. 85): S-35-9.
[PMID: 25365087]
[18]
Maksymowych WP, Naides SJ, Bykerk V, et al. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol 2014; 41(11): 2104-13.
[http://dx.doi.org/10.3899/jrheum.131446] [PMID: 25128504]
[19]
Kilani RT, Maksymowych WP, Aitken A, et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol 2007; 34(8): 1650-7.
[PMID: 17611984]
[20]
Maksymowych WP, van der Heijde D, Allaart CF, et al. 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther 2014; 16(2): R99.
[http://dx.doi.org/10.1186/ar4547] [PMID: 24751211]
[21]
Robinson P. Sonography of common tendon injuries. AJR Am J Roentgenol 2009; 193(3): 607-18.
[http://dx.doi.org/10.2214/AJR.09.2808] [PMID: 19696272]
[22]
LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15(2): 202-5.
[PMID: 3361530]
[23]
Ahmed R, Nazarian LN. Overview of musculoskeletal sonography. Ultrasound Q 2010; 26(1): 27-35.
[http://dx.doi.org/10.1097/RUQ.0b013e3181ce43ed] [PMID: 20216192]
[24]
Kay Jonathan. Katherine S Upchurch, ACR/EULAR 2010 rheumatoid arthritis classification criteria Rheumatol 2012; 51(suppl_6): S5-9
[http://dx.doi.org/10.1093/rheumatology/kes279]
[25]
Fransen J, Stucki G, van Riel PL. Rheumatoid arthritis measures: Disease activity score (DAS), Disease activity score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid arthritis disease Activity Index (RADAI). Arthritis Care Res 2003; 49: S214-24.
[http://dx.doi.org/10.1002/art.11407]
[26]
Larsen A, Thoen J. Hand radiography of 200 patients with rheumatoid arthritis repeated after an interval of one year. Scand J Rheumatol 1987; 16(6): 395-401.
[http://dx.doi.org/10.3109/03009748709165409] [PMID: 3423748]
[27]
Backhaus M, Burmester GR, Gerber T, et al. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001; 60(7): 641-9.
[http://dx.doi.org/10.1136/ard.60.7.641] [PMID: 11406516]
[28]
Ohrndorf S, Fischer IU, Kellner H, et al. Reliability of the novel 7-joint ultrasound score: results from an inter- and intra-observer study performed by rheumatologists. Arthritis Care Res (Hoboken) 2012; 64(8): 1238-43.
[PMID: 22438306]
[29]
Østergaard M, Peterfy C, Conaghan P, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003; 30(6): 1385-6.
[PMID: 12784422]
[30]
Dawson B, Trapp R. Basic and Clinical Biostatistics 4th Edition, New York, United States Mcgraw-Hill Medical Publishing Inc 2004; 23(61): 245.
[31]
Jaskowski TD, Hill HR, Russo KL, Lakos G, Szekanecz Z, Teodorescu M. Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies. J Rheumatol 2010; 37(8): 1582-8.
[http://dx.doi.org/10.3899/jrheum.091236] [PMID: 20516016]
[32]
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an american college of rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2010; 62(9): 2569-81.
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[33]
Machold KP, Stamm TA, Eberl GJ, et al. Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002; 29(11): 2278-87.
[PMID: 12415582]
[34]
Muller PC, Anink J, Shi J, et al. Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients. Ann Rheum Dis 2013; 72(12): 2053-5.
[http://dx.doi.org/10.1136/annrheumdis-2013-203650] [PMID: 23873877]
[35]
Maksymowych WP, Marotta A. 14-3-3η: a novel mediator upregulated by TNFα, reflects clinical response to anti-TNFα therapy. Arthritis Rheum 2011; (63): (Suppl. 10): S162-3.
[36]
Othman MA, Wan WS, Ghazal M. Hamid WZWA, Won KK, Yahya NK. Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor. Saudi Med J 2017; 38-9.
[37]
Mohamed AH, Enein A, Abdelsalam N, et al. Utility of anti-carbamylated protein antibodies in the diagnosis of early rheumatoid arthritis. Indian J Rheumatol 2019; 14(1): 37-41.
[http://dx.doi.org/10.4103/injr.injr_110_18]
[38]
Pecani A, Alessandri C, Spinelli FR, et al. Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. Arthritis Res Ther 2016; 18(1): 276.
[http://dx.doi.org/10.1186/s13075-016-1173-0] [PMID: 27887639]
[39]
Kucuksahin BO, Yeşil TH, Akan S, Erten S. Sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2018; 77-2.
[40]
Shi J, van Steenbergen HW, van Nies JAB, et al. The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis Res Ther 2015; 17: 339.
[http://dx.doi.org/10.1186/s13075-015-0860-6] [PMID: 26601692]
[41]
Novikov A, Aleksandrova E, Cherkasova M, et al. diagnostic value of 14-3-3 (eta) in rheumatoid arthritis. Annals of The Rheum Dis 2017; 76:(Suppl 2).
[42]
Maksymowych WP, Naides SJ, Bykerk V, et al. Serum 14-3-3 is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol 2014;41: 11
[http://dx.doi.org/10.3899/jrheum.131446]
[43]
Dasgupta B, Cherkas Y, Lamberth S, et al. Serum 14-3-3 ETA is an RA specific mechanistic marker. J Rheumatol 2014; 41(11): 2104.
[44]
Serum level of 14-3-3η (eta) protein as a diagnostic marker for rheumatoid arthritis and potential correlation with disease activity. MOJ Orthop Rheumatol 2018; 7-4.
[45]
Zickuhr L, Pourpaki M, Brooks MM, Joseph A. 14-3-3η: Useful for more than the diagnosis of rheumatoid arthritis? Arthritis Rheumatol 2017; 69: (suppl 10)
[46]
Schaardenburg DV, Turk S, Bores M, Walter M. 14-3-3η is an independent predictor of radiographic changes in early RA and higher titers inform a higher likelihood of joint damage progression. Ann Rheum Dis 2014; 73(Suppl. 2): 266.
[47]
Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther 2015; 17: 280.
[http://dx.doi.org/10.1186/s13075-015-0799-7] [PMID: 26449724]
[48]
Berglin E, Hallmans G. Serum 14-3-3η predicts the risk of RA development and its higher titers are associated with higher risk. Ann Rheum Dis 2014; 73.
[49]
Chao R, Das M, Purat N, et al. 14–3–3eta positivity is associated with higher rheumatoid arthritis disease activity measured by multi-biomarker disease activity assay. Ann Rheum Dis 2018; 77: 1326-7.
[50]
Humphreys JH, Verheul MK, Barton A, et al. Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk arthritis register. Ann Rheum Dis 2016; 75(6): 1139-44.
[http://dx.doi.org/10.1136/annrheumdis-2015-207326] [PMID: 26443608]
[51]
Truchetet ME, Dublanc S, Barnetche T, et al. Association of the presence of anti–carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: data from the French ESPOIR cohort. Arthritis Rheumatol 2017; 69(12): 2292-302.
[http://dx.doi.org/10.1002/art.40237] [PMID: 28853240]
[52]
Humphreys JH, Verheul MK, Barton A, et al. Anti-CarP antibodies linked to increased disability, disease activity in patients with RA. Ann Rheum Dis 2015; 75: 1139-44.
[http://dx.doi.org/10.1136/annrheumdis-2015-207326] [PMID: 26443608]
[53]
Reyes A. Anti-CarP Antibodies linked to disability in patients with polyarthritis rheumatology network 2015 Available from: https://www.rheumatologynetwork.com/rheumatic-diseases/anti-carp-antibodies-linked-disability-patients-polyarthritis
[54]
Yee A, Webb T, Seaman A, et al. Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol Res 2015; 61: 24-30.
[55]
Jagpal A, Navarro-Millan I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment, and treatment Jagpal and Navarro-Millán BMC Rheumatol 2018; 2(10)
[56]
Spinelli FR, Pecani A, Ciciarello F, et al. Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients. BMC Musculoskelet Disord 2017; 18(1): 214.
[http://dx.doi.org/10.1186/s12891-017-1563-8] [PMID: 28545441]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 7
ISSUE: 2
Year: 2020
Published on: 14 July, 2020
Page: [141 - 153]
Pages: 13
DOI: 10.2174/2213476X07666200120111549
Price: $25

Article Metrics

PDF: 14
HTML: 1